Seqvera

What Seqvera does

Seqvera Ltd. Oy is a Finnish private limited company headquartered in Helsinki's Terkko Health Hub that provides specialized testing, validation, and analytical services for biomaterials, medical devices, pharmaceutical products, advanced therapy medicinal products (ATMPs), substances of human origin (SoHO), and 3D bioprinted constructs. The company was established to commercialize BEST (Biomaterials Enhanced Simulation Testing), a patented methodology portfolio that combines coherent physiological stimulation with idempotent mathematical analysis to generate model-free, clinically relevant data for material behavior prediction. Its intellectual property includes granted US patents on injectability testing (US10,809,171 B2), biomaterials testing (US10,379,106 B2), and auto-mechano-induction in cell development, plus a patent-pending Drug Transport Signature (DTS) method. Seqvera operates as a boutique professional services provider with non-public, customized pricing and NDA-protected engagements, primarily targeting enterprise medical device, biomaterials, and pharmaceutical developers. Its commercial visibility is anchored by EU research project participation (LIFESAVER under Horizon 2020, CARE-IN-HEALTH under Horizon Europe), scientific conference presence, and a documented collaboration with Askel Healthcare Ltd. on dental abutment optimization. The company is privately held with no disclosed investors, parent, or external funding rounds.

Name

Seqvera

Legal name

Seqvera Ltd. Oy

Website

https://seqvera.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Seqvera Ltd. Oy is a Finnish specialist services firm that provides BEST (Biomaterials Enhanced Simulation Testing), a patented methodology for physiologically relevant testing and validation of biomaterials, medical devices, and pharmaceutical products. It serves enterprise healthtech, medtech, and pharmaceutical developers seeking MDR-compliant data.

Ownership category

akta.pro rank

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Testing and Analysis Services: Seqvera provides solutions for design, development, testing and validation of biomaterials, medical devices and other products. Services include coherent testing, idempotent analysis, and model-free data extraction for optimization of biomedical solutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Seqvera provides testing and validation services for biomaterials, medical devices, medicinal products, ATMP/SoHO applications, and 3D bioprinted products using its patented BEST (Biomaterials Enhanced Simulation Testing) methodology. The company delivers coherent stimulation testing combined with idempotent analysis to produce model-free data under physiologically relevant conditions, supporting regulatory compliance with MDR 2017/745 and 3R principles. Services include tailored analysis, retrospective data reprocessing, and SOP development assistance.

Product overview

Seqvera offers a single unified product/service centered on BEST (Biomaterials Enhanced Simulation Testing) - a patented methodology comprising several patented techniques for tailored and integrated analysis of materials, tissues, devices, and injectable hydrogels. The BEST approach combines coherent stimulation testing with idempotent analysis to generate model-free data. Services include both pro- and retrospective data analysis, SOP development assistance, and regulatory compliance support for medical devices, biomaterials, ATMP/SoHO products, and 3D bioprinted products under MDR 2017/745.

Differentiator

Problem solved

Functional benefit

Brands

• BEST (Biomaterials Enhanced Simulation Testing): The core patented methodology for testing biomaterials, medical devices, tissues, and injectable hydrogels under physiologically relevant conditions to generate model-free data for material optimization and behavior prediction.

Products and services

• BEST (Biomaterials Enhanced Simulation Testing)

Quantifiable outcome

• Shortens time and costs of materials development and optimization
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• LIFESAVER ProjectcoreStrategic or Co-development PartnerEU Horizon 2020 project addressing unmet needs in creating a valid scientific knowledge base for development and implementation of regulatory approaches relevant to maternal and fetal health. It aims to generate and validate effects data of environmental pollutants and pharma treatments for pregnant women. Grant Agreement No 101036702.
• CARE-IN-HEALTHcoreStrategic or Co-development PartnerCardiovascular Resolution of Inflammation to promote Health project addressing chronic inflammation during transition from health to cardiovascular disease. Funded under EU Horizon Europe program, Grant Agreement No 101095413.
• Askel Healthcare Ltd.minorStrategic or Co-development PartnerCollaboration where BEST method was used to generate valuable data for development of new dental abutments. Quote from CTO: 'The BEST method has given us valuable data which we would not be able to get otherwise.'

Recent moves5 records

Expansion highlights5 records

Direct peers

• NAMSA: World's largest medical device-focused CRO, offering biological, toxicology, and materials testing services to medical device manufacturers. Directly comparable to Seqvera as a regulatory-aligned, biomaterials-and-medical-device testing provider serving compliance-driven workflows.
• Toxikon (LabCorp / Fortrea): Specialized medical device and pharmaceutical testing laboratory, now part of Fortrea (formerly LabCorp Drug Development). Directly comparable to Seqvera in delivering preclinical and biocompatibility-focused testing for medical devices.
• Nelson Labs (Sotera Health): Specialized laboratory testing services for medical devices and pharmaceutical companies, with focus on sterility, biocompatibility, and packaging. Comparable to Seqvera in delivering device/biomaterials testing that supports MDR and FDA compliance.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO providing laboratory testing, bioanalysis, and medical device testing services. Comparable to Seqvera's biomaterials and medical device testing offering, scaled to a much larger diversified platform.
• Intertek: Global quality assurance and testing company with strong medical device and pharmaceutical testing offerings. Comparable to Seqvera across multiple testing verticals, but at much larger scale and broader service portfolio.
• SGS: Global testing, inspection, and certification company with a dedicated life sciences / medical device testing portfolio. Comparable to Seqvera as a regulatory-anchored testing provider for medical device manufacturers and pharma companies.
• Charles River Laboratories: Large global CRO offering preclinical, biomedical, and medical device testing services. Comparable to Seqvera as a comprehensive testing partner for medical device and drug developers, though much broader and with significantly greater scale.
• TÜV SÜD: Global certification and testing body with strong medical device testing and MDR compliance services. Comparable to Seqvera in providing MDR-aligned testing and validation for medical device manufacturers in Europe.
• BSI Group: Standards and certification body with medical device testing and notified body services. Comparable to Seqvera as a compliance-focused testing/validation partner for medical device companies operating under MDR.
• Eurofins Scientific: Global testing services group operating across pharmaceutical, medical device, and biomaterials testing. Relevant as a competitor offering laboratory testing and validation services across Seqvera's target verticals, though at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/seqvera

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seqvera